Sava Infond D.O.O. Biomarin Pharmaceutical Inc Transaction History
Sava Infond D.O.O.
- $566 Billion
- Q4 2024
A detailed history of Sava Infond D.O.O. transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Sava Infond D.O.O. holds 3,250 shares of BMRN stock, worth $209,365. This represents 0.04% of its overall portfolio holdings.
Number of Shares
3,250Holding current value
$209,365% of portfolio
0.04%Shares
1 transactions
Others Institutions Holding BMRN
# of Institutions
640Shares Held
182MCall Options Held
2.07MPut Options Held
1.36M-
Black Rock Inc. New York, NY22.7MShares$1.46 Billion0.04% of portfolio
-
Vanguard Group Inc Valley Forge, PA19.4MShares$1.25 Billion0.02% of portfolio
-
Primecap Management CO Pasadena, CA18.2MShares$1.17 Billion0.94% of portfolio
-
Dodge & Cox San Francisco, CA14.7MShares$950 Million0.61% of portfolio
-
Capital Research Global Investors Los Angeles, CA13MShares$837 Million0.18% of portfolio
About BIOMARIN PHARMACEUTICAL INC
- Ticker BMRN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,824,000
- Market Cap $12B
- Description
- BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...